Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or quantitative data synthesis
PubMed 39957814 · doi:10.30476/ijms.2024.101739.3446
What was done
This narrative review synthesized the biological mechanisms, therapeutic efficacy, associated challenges, and adverse effects of Chimeric Antigen Receptor (CAR) T-cell therapies and Bispecific T-cell Engagers (BiTEs) in patients with multiple myeloma based on available literature.
What was found
The abstract reports no numerical findings, sample sizes, or response rates. It notes qualitatively that both CAR T-cell therapies (primarily targeting BCMA) and BiTEs (targeting CD3 and tumor-associated antigens) have achieved clinical efficacy and FDA approvals in selected multiple myeloma populations, accompanied by toxicities including cytokine release syndrome (CRS) and neurotoxicity.
Why it matters
It summarizes current T-cell-directed immunotherapeutic strategies for multiple myeloma, framing their translational role and primary safety considerations.
Limits
The publication is a narrative review that does not report systematic search criteria, meta-analytic pooling, or new empirical data. The abstract provides no quantitative metrics or comparative efficacy outcomes.
Cited by
- supports Bispecific T-cell engagers (BiTEs) are dual-binding antibodies designed to simultaneously bind a target on a cancer cell and a target on a T cell, directing endogenous T cells to kill the cancer cell without requiring genetic modification of the T cells.